Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 8/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loviride SCHEMBL29457001 | 1.00 | ALOX15 (0.39) | ALOX15RAB9ANPC1PKMSMN1; SMN2 | |
| Loviride SCHEMBL29456999 | 1.00 | ALOX15 (0.39) | ALOX15RAB9ANPC1PKMSMN1; SMN2 | |
| Loviride SCHEMBL247781 | 1.00 | ALOX15 (0.39) | ALOX15RAB9ANPC1PKMSMN1; SMN2 | |
| SCHEMBL14002485 | 0.94 | ALOX15 (0.37) | ALOX15RAB9ANPC1PKMSMN1; SMN2 | |
| SCHEMBL14459555 | 0.89 | PTGS2 (0.35) | ALOX15RAB9ANPC1PKMSMN1; SMN2 | |
| SCHEMBL8830304 | 0.89 | GRIK1 (0.39) | RAB9ANPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL8830196 | 0.86 | CLCN2 (0.36) | PKMLMNAGAAKMT2AHPGD | |
| (R)-Loviride SCHEMBL23752280 | 0.85 | ALDH1A1 (0.38) | RAB9ANPC1SMN1; SMN2LMNAL3MBTL1 | |
| (R)-Loviride SCHEMBL31126600 | 0.85 | ALDH1A1 (0.38) | RAB9ANPC1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL8830164 | 0.84 | KDM4E (0.43) | RAB9ANPC1PKMSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7114 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| US-12595280-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2026-04-07 | — | — | US | claimed |
| US-20260092059-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260091068-A1 | METHODS FOR TREATING AND PREVENTING DISEASES | Tets, Viktor Veniaminovich (US) | 2026-04-02 | — | — | US | claimed |
| EP-3534910-B1 | RIFAMPICIN DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | POP TEST ONCOLOGY LLC (US) | 2026-03-25 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260060964-A1 | METHODS AND COMPOSITIONS FOR TREATING SEPSIS | ANTIVIRUS THERAPEUTICS (US) | 2026-03-05 | — | — | US | claimed |
| EP-0799309-A1 | RIBOZYMES TARGETING THE RETROVIRAL PACKAGING SEQUENCE EXPRESSION CONSTRUCTS AND RECOMBINANT RETROVIRUSES CONTAINING SUCH CONSTRUCTS | GENE SHEARS PTY. LTD. (AU) | 1997-10-08 | — | — | EP | claimed |
| WO-1997027480-A1 | METHOD OF MANAGING THE CHEMOTHERAPY OF PATIENTS WHO ARE HIV POSITIVE BASED ON THE PHENOTYPIC DRUG SENSITIVITY OF HUMAN HIV STRAINS | VIRCO N.V. (BE) | 1997-07-31 | — | — | WO | claimed |
| CN-1151697-A | Anti-hiv triple combination | JANSSEN PHARMACEUTICA NV (BE) | 1997-06-11 | — | — | CN | claimed |
| WO-1997018839-A1 | SOLID MIXTURES OF CYCLODEXTRINS PREPARED VIA MELT-EXTRUSION | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-05-29 | — | — | WO | claimed |
| EP-0768881-A2 | ANTI-HIV TRIPLE COMBINATION | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-04-23 | — | — | EP | claimed |
| WO-1996022368-A1 | RIBOZYMES TARGETING THE RETROVIRAL PACKAGING SEQUENCE EXPRESSION CONSTRUCTS AND RECOMBINANT RETROVIRUSES CONTAINING SUCH CONSTRUCTS | GENE SHEARS PTY. LTD. (AU) | 1996-07-25 | — | — | WO | claimed |
| CN-1118137-A | Method of reversing zidovudine resistance of HIV-1 strains | JANSSEN PHARMACEUTICA NV (BE) | 1996-03-06 | — | — | CN | claimed |
| WO-1996001110-A2 | ANTI-HIV TRIPLE COMBINATION | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-01-18 | — | — | WO | claimed |
| EP-0684818-A1 | METHOD OF REVERSING RESISTANCE OF HIV-1 STRAINS TO ZIDOVUDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-12-06 | — | — | EP | claimed |
| WO-1994018963-A1 | METHOD OF REVERSING RESISTANCE OF HIV-1 STRAINS TO ZIDOVUDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-09-01 | — | — | WO | claimed |